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Prostaglandin-mediated loss of proteins during peritonitis in
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Prostagiandin-mediated loss of proteins during peritonitis in continuous
ambulatory peritoneal dialysis. The loss of proteins into the dialysate
and the peritoneal generation of the immunoreactive prostanoids PGE2,
6-keto-PGF1a, PGF2a, and TXB2 were studied in 12 patients undergoing
continuous ambulatory peritoneal dialysis (CAPD) during 16 episodes
of peritonitis and in inflammation-free periods. Protein permeability,
defined as the ratio of dialysatclplasma protein (DIP), decreased with
increasing molecular weight, independent of the condition of the
peritoneum. With peritonitis a general rise of permeability was noticed
for total protein (TP) and the individual proteins j32-microglobulin
(/3MG), albumin (Alb), immunoglobulin G (IgG), and cs2-macroglobulin
(aMG) (P C 0.001). Simultaneously, an increase of dialysate prosta-
noids occurred with predominance of the vasodilative acting prosta-
glandins PGI2, determined as its metabolite 6-keto-PGF1a, and PGE2 by
factors of 8,4 and 9,7, respectively (P C 0.001), in comparison to
peritonitis-free control. In the early phase of peritonitis (0 to 12 hr after
the onset of therapy) the augumcnted peritoneal prostaglandin synthesis
correlated positively with the increased permeability of TP (r 0.7446,
P C 0.01) and the individual proteins p3MG, Alb, IgG, and aMG (r
0.5970, P c 0.05). Inhibition of cyclo-oxigenase activity by local
administration of indomethacin inhibited both the generation of 6-keto-
PGF1 and PGE2 by 39 and 42%, respectively (P C 0.05), and the
peritoneal loss of TP by 34% (P C 0.05). In the absence of peritonitis
indomethacin only diminished the synthesis of PGE2 whereas the
generation of the other prostanoids remained unchaaged. No effect
occurred on peritoneal protein loss. The present data suggest that
vasoactive prostaglandins are involved in the pathophysiology of in-
creased peritoneal protein losses in the early phase of CAPD-associated
peritonitis.
Continuous ambulatory peritoneal dialysis (CAPD) has be-
come an alternative treatment to chronic hemodialysis for
patients with endstage renal failure. Besides peritonitis and
catheter obstruction, continuous protein loss is one of the main
disadvantages of this dialysis technique [14]. Considerable
between patient variations in protein loss are observed in
CAPD [2, 5]. During peritoneal inflammation there is a marked,
general increase of peritoneal protein permeability [2, 4, 6] and
various endogenous factors are supposed to be involved in
changes of the peritoneal transport properties during peritoni-
tis, including histamine and bradykinin [7, 8] and activated
complement factors [9]. Recent investigations reveal a local
generation of vasoactive prostanoids during peritonitis, espe-
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cially prostacyclin (POT2) and prostaglandin (PG)E2 [10]. Since
both prostaglandins are capable of augmenting local blood flow
and vascular permeability [11, 12], the hypothesis arose that the
enhanced peritoneal mass transport during peritonitis is medi-
ated by vasoactive prostanoids [10].
The present investigation was performed to study whether
prostaglandins are involved in the pathophysiology of the
increased protein permeability during peritonitis. For this pur-
pose the peritoneal release of 6-keto-PGF1a, POE2, POF2a, and
thromboxane (TX)B2 was measured during peritonitis and in
infection-free periods. Protein permeability was determined by
measurement of total protein (TP) and individual proteins in
serum and dialysate effluent. /32-microglobulin (/3MG, MW
11,600 daltons), albumin (Alb, MW 65,000 daltons), immuno-
globulin 0 (TgG, MW 156,000 daltons), and a2-macroglobulin
(aMG, MW 820,000 daltons) were chosen on the basis of their
molecular weight to obtain information on the peritoneal per-
meability of the whole molecular weight range of serum pro-
teins. For further evaluation of prostanoid action on peritoneal
permeability, the effect of local cyclo-oxigenase inhibition on
protein loss and the peritoneal generation of prostaglandins and
thromboxane (TX)B2 was studied.
Methods
Twelve patients (3 females, 9 males; mean age 42.6 3.4
years; age range, 24 to 65 years) with endstage renal failure
undergoing continuous ambulatory peritoneal dialysis were
studied in the Nephrological Department of the University of
Freiburg. The patients underwent study dialysate exchanges
during 16 episodes of bacterial peritonitis and when they were
clinically well. Informed consent was obtained from all patients
prior to the study.
Dialysis technique. CAPD was performed with dialysis solu-
tions containing identical dextrose concentrations (1.36% anhy-
drous dextrose, Dianeal, Travenol, Dearfield, Illinois, USA;
1.5% dextrose monohydrate, Fresenius, Bad Homburg, Federal
Republic of Germany). The fluid volume was 2.0 liters with a
dwell time of 6 hr. Peritonitis was diagnosed by the clinical sign
of abdominal tenderness accompanied by an elevated dialysate
white blood cell count (WBC) above 3001mm3 and/or a positive
bacterial dialysate culture.
Therapy consisted of three rapid in-and-out exchanges of
2.0-liter dialysis solution without additives, followed by the
intra-abdominal administration of antibiotics and heparin (500
U/liter) into the dialysis fluid with the regular dwell time of 6 hr.
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The primary antibiotic treatment initially consisted of cefotax-
ime 200 mg/liter and tobramycin 16 mg/liter dialysis solution,
followed by cefotaxime 100 mg/liter and tobramycin 8 mg/liter
for 5 to 7 days after the first negative dialysate cultures were
obtained.
Study A. Twelve episodes of uncomplicated peritonitis in 12
patients were studied with regard to peritoneal permeability and
local generation of prostanoids. All inflammations promptly
responded to the primary antibiotic treatment.
Study B. In four episodes of peritonitis in four patients
(patients 2, 5, 7, and 11) resistant to the primary antibiotic
treatment, indomethacin 12.5-mg/liter dialysate was adminis-
tered intra-abdominally in addition to antibiotics and heparin
for four consecutive dialysate instillations during 24 hr. The
effect of indomethacin was studied on peritoneal prostanoid
generation and protein permeability. After determining antibi-
otic sensitivity, the appropriate antibiotic treatment was started
and further instillation of indomethacin was discontinued.
Intraperitoneal administration of indomethacin (12.5 mg/liter
dialysate, four consecutive dialysate instillations, dwell time of
6 hr each) was repeated in the absence of peritonitis 3 to 6
weeks after discontinuation of antibiotic treatment.
Dialysate and blood handling. Dialysate effluent was collected
consecutively for 7 days from the first exchange after the diagnosis
of peritonitis. Control exchanges were obtained after a period of 3
to 6 weeks without clinical and laboratory signs of peritoneal
inflammation after discontinuation of antibiotic therapy.
Venous blood samples were collected before the start of
therapy and daily during the peritonitis and the control periods
before the first dialysate exchange of the day. Samples of
dialysate and blood were cooled to 4°C abruptly after collection
and centrifuged at x 3,000 g for 15 mm to remove cellular
components. The supernatants were stored at —20°C till further
analysis.
Chemical analysis and radioimmunoassays. Dialysate total
protein concentration was measured by the Biuret method [13].
/32-Microglobulin was determined by radioimmunoassay [14]
(Pharmacia Diagnostics, Uppsala, Sweden), albumin, IgG, and
a2-macroglobulin by radial immunodiffusion [15] (Behring-
werke, Marburg, Federal Republic of Germany).
The prostanoids 6-keto-PGF1, PGE2, PGF2a, and TXB2
were determined by specific and sensitive radioimmunoassays
as previously described by Dray, Charbonnel, and Maclouf [16]
and our group [10, 17], that is, prostanoids were extracted and
separated on TLC prior to the assay. The recoveries of various
amounts of 6-keto-PGF1,. and PGE2 to charcoal-absorbed dial-
ysis effluent (0.2 ml charcoal suspension, 20 mg/nil PBS, added
to 1 ml dialysate, incubated for 20 mm at 4°C, separated by
centrifugation) were 76 and 88%, respectively.
Parallel results were obtained between dose-response curves
and serial dilutions of unknown samples of peritoneal dialysate.
The coefficients of variation for intra- and inter-assay variation
were below 5.8 and 7.1%, respectively.
Calculations and statistics. Dialysate net drainage volume
was determined by subtracting the weight of the bag before
infusion from the bag after dialysate efflux. Pentoneal solute
clearances were calculated as drainage volume (ml) x drainage
concentration/serum concentration x dialysis time (mm). Total
protein, albumin, f32-microglobulin, immunoglobulin G, and
Table 1. Characteristics of patients undergoing continuous
ambulatory peritoneal dialysis
Patient
no
Age
years Sex Diagnosis
Time on
CAPD
months
Episodes
of pen-
tonitis
1 55 M Mesangial proliferative
glomerulonephritis
35 7
2 51 F Focal glomerulosciero-
sis
26 5
3 32 M Chronic glomerulone-
phritis
8 4
4 65 M Membranoproliferative
glomerulonephritis
18 4
5 36 F Chronic glomerulone-
phritis
35 7
6 56 M Diabetes mellitus 22 5
7 35 M Chronic glomerulone-
phritis
20 5
8 40 M Alport syndrome 29 3
9 35 M Chronic glomerulone-
phritis
20 3
10 24 M Membranous glomeru-
lonephritis
27 4
11 43 F Chronic interstitial
nephritis
35 3
12 39 M Mesangial proliferative
glomerulonephritis
12 3
Means 23.9 4.4
SEM
a2-macroglobulin losses as well as prostanoid generation were
calculated by multiplying the dialysate concentrations by the
drainage volume.
The patients underwent consecutive measurements during
peritonitis and inflammation-free periods. The data were eval-
uated by Student's t test and linear regression analysis. Values
are given as means 5EM; the null hypothesis was rejected at
P < 0.05.
Results
Table 1 summarizes the characteristics of patients in the
study. They showed an incidence of 2.2 episodes of peritonitis
per year. Nine out of 16 peritonitis episodes were caused by
gram-positive microorganisms (Staphylococcus epidermidis,
Staphylococcus aureus); six episodes were caused by gram-
negative microorganisms (aerobic spore producer, Acineto-
bacter Iwoffi, Pseudomonas species). Negative bacterial cul-
tures were obtained in one episode of peritonitis. The mean
dialysate white blood cell count at admission to the hospital was
1240 200/mm3 (range, 590 to 3200/mm3).
Study A
Peritonitis was associated with significantly decreased ultra-
ifitration and increased release of prostanoids into the dialysate
(Table 2). The maximal amounts of immunoreactive 6-keto-
PGF1. and PGE2 in dialysis effluent (first 6-hr period) exceeded
the amounts obtained during inflammation-free control periods
by 8.3 and 9.7 times, respectively. The release of immunoreac-
tive PGF2,. and TXB2 increased 4.8 and 5.3 times, respectively
(first 6-hr period) in comparison to control periods. The dialy-
sate prostanoids remained increased during the first 36 hr after
hospitalization.
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Table 2. Peritoneal generation of prostanoids and net ultrafiltration during peritonitis and in the absence of inflammation
in patients undergoing CAPD"
Day of
peritonitis
Net ultrafiltration
rnlI6 hr
6-keto-POF1a
/hg16 hr
PGE2
ng/6 hr
POF2a
ng/6 hr
TXB2
ngI6 hr
1 Period I
Period II
Period III
PeriodlV
102 21
98 16
96 18
118±20
7,35 1.12t
2.37 O,37e
1.76 0.21
1.38±0.13
1321 318"
679 161"
542 183t
364± 63"
526 1231
283 7&
211 81
176± 66
307 62d
136 31C
83 29
61±22
2 Period 1
Period II
Period III
Period IV
132 12
142 16
120 31
167 17
1.22 0.28
1.27 0.24
1.08 0.24
0.96 0.19
326 125
353 134
226 101
170 67
130 32
157 48
125 20
102 21
67 20
74 18
64 12
58 12
3 Periodl
Period II
Period III
PeriodlV
186±19
172 22
205 26
192± 19
1.13±0.20
1.10 0.23
1.24 0.31
1.21±0.26
125± 52
152 89
189 104
164± 90
124± 23
108 32
127 26
110± 28
60±21
52 19
45 13
53± 16
4 Periodl
Periodll
Period III
Period IV
238±27
213±24
210 22
233 25
1.08±0.19
0.86±0.13
0.96 0.10
0.84 0.16
127± 72
103± 37
130 57
148 46
93± 12
86± 24
121 33
108 27
58±19
28± 14
56 20
50 14
Controlb 248 28 0.88 0.06 136 21 110 24C 58 16C
a Each period represents the results of 6 hr of dialysis time; values are means 5EM, N = 12.
b Values represent the mean of four dialysates per patient.
P < 0.001 in comparison to control.
"P C 0.005.
P C 0.05.
' N = 9.
The influence of peritonitis on the loss of total protein and
individual proteins of various molecular weight is summarized
in Table 3. A significant increase in peritoneal permeability
during peritonitis was observed for all proteins investigated,
independent of the molecular weight. The loss of total protein
increased from 8.4 0.8 g124 hr (range, 6.1 to 12.4 g124 hr) in
the absence of inflammation to 17.5 1.2 gI24 hr (range, 11.7 to
34.2 g124 hr) on the first day of peritonitis. By individual protein
analysis, 83.1 1.2% (range, 73.3 to 92.0%) of total peritoneal
protein loss could be identified. Peritoneal protein permeability
is expressed as the ratio dialysate/plasma protein concentration
(D/P). The individual DIP ratios decreased as a function of the
molecular weight (Fig. 1). During peritonitis the DIP ratios
increased for all proteins investigated and lead to a parallel shift
of the exponential permeability profile obtained in the absence
of inflammation (Fig. 1).
The relationship between protein loss and peritoneal release
of 6-keto-PGF,, is shown in Table 4. Albumin loss significantly
correlated with 6-keto-PGF,,, release within the first 18 hr of
peritonitis, total protein, IgG, and a2-macroglobulin within the
first 12 hr and /32-microglobulin within the first 6 hr. In all
further study periods during peritonitis and in the absence of
peritoneal inflammation, there was no relationship between
quantities of protein lost and the peritoneal release of 6-keto-
POF1.. Correlation between total protein loss and dialysate
6-keto-PGF1a within the first and second 6-hr period and in the
absence of inflammation are demonstrated in Figs. 2 and 3.
Significant relationships were also obtained between peritoneal
release of POE2 and total protein loss as well as all individual
protein losses investigated within the first 12 hr of the peritonitis
study (r = 0.5897 — 0.6931, P < 0.05). The loss of albumin and
total protein also correlated with the release of PGF2a during
the first 6-hr period (r 0.6627 and 0.5961, respectively; P <
0.05). No relationship existed between dialysate TXB2 and
protein loss.
Study B
In four episodes of peritonitis resistant to the primary antibi-
otic treatment, peritoneal generation of prostanoids was inhib-
ited by intraperitoneal administration of the cyclo-oxigenase
inhibitor indomethacin for 24 hr.
Steady-state conditions were maintained during this time.
Indomethacin at a concentration of 12.5 mglliter dialysate
inhibited the release of 6-keto-POF1,. and POE2 by 39 and 42%,
respectively (P < 0.05), and total protein loss by 34% (P <
0.05). In the absence of peritonitis, indomethacin only dimin-
ished the peritoneal generation of PGE2, whereas no significant
effect was observed on the synthesis of further prostanoids and
the peritoneal protein loss (Table 5).
Discussion
The present studies were intended to characterize the perito-
neal protein loss during CAPD-assoeiated peritonitis and to
demonstrate its partial relationship to locally generated
prostanoids. For this purpose, in addition to the total protein
loss in dialysate, individual proteins, selected according to their
molecular weights (11,600 to 900,000 daltons) were determined.
All data were pooled regardless of patient characteristics, since
no consistent differences in peritoneal transport properties with
Prostaglandin-mediated protein loss
Table 3. Loss of proteins during peritonitis and in the absence of inflammation in patients undergoing CAPD
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Fig. 1. Relation of dialysate/plasma protein (D/P) during peritonitis
(open circles) and in the absence of inflammation (closed circles) on
molecular weight, Abbreviations: /3MG, /32-microglobulin; Alb, albu-
min; IgG, immunoglobulin G; aMG, a2-macroglobulin.
age, sex, time on CAPD, or number of pentonitis episodes have
been found [2, 5, 15, 18, 19].
During the initial phase of peritonitis an excessive increase of
protein loss in the dialysate occurred which returned to baseline
levels within a few days under effective antibiotic treatment.
This observation agrees with the investigations of Rubin et a!
[20] and Blumenkrantz et a! [2] who found peritoneal protein
loss normalized within 1 week of initiation of therapy. The
increase of the peritonitis-associated protein loss was seen for
all individual proteins investigated and was independent of their
molecular weight. The ratio D/P on the basis of milligrams of
protein per 100 ml of dialysate and serum, respectively, was
used to define peritoneal permeability. The DIP ratio was found
to be highest for /3-MG (MW 11,600 daltons, DLP:0.120); lower
ratios were observed for albumin (MW 65,000, DIP:0.0l6), IgG
(MW 156,000, DIP:0.010), and aMG (MW 820,000, D/P:0.004)
indicating decreasing peritoneal permeability with increasing
molecular weight as previously proposed by Kuska [21],
Giangrande et a! [22], and Boesken et al [23]. Plotted on a
log/log scale the permeability profile of individual proteins
aMG revealed an exponential character. Increased protein losses
02 during peritonitis resulted in a parallel shift of the permeability
curve (Fig. 1).
Since no changes of the permeability profiles occurred for
IgG and /3MG, that is, proteins which are known to be gener-
ated during acute inflammation, it is reasonable to assume that
no essential local generation of both proteins occurs during
peritonitis, at least in cases without complications as included
in the present study. The hypothesis of Dulaney and Hatch [24]
that dia!ysate proteins could result from synthesis by cells
within the peritoneal cavity is not supported by our study of the
individual proteins investigated. In contrast, the protein
lysozyme (MW 14,300 daltons) is thought to be generated
locally by polymorphonuclear leukocytes in measurable
amounts since an overproportional increase of lysozyme
"clearance" was observed during peritonitis, compared to
various proteins of similar molecular weights [25].
Total protein /32-Microglobulin
D S
mg/6 hr mg/dl
Albumin IgGe
D
mg/6 hr
S
mg/dl
2Macroglobulind
D S
mg/6 hr mgldl
Dayof
peritonitis
D
g/6 hr
S
gIdi
D
g/6 hr
S
gIdi
1 Period I
Period II
Period III
Period IV
7.37 0.51e
3.51 O.33
3.38 0.22e
3.25 O.23
6.81 44.5 9.4
30.7 4,4e
26.2 2.3e
23.9 4.2
4.8 4.31 0.32e
2.23 O.23
2.13 0.22
2.20 O.l6
3.94 972 l35617 l24
578 86
552 103
1330 80.6 ll.3e
57.1 9,75
38.4 6.2
42.7 7.0k
262
2 Period I
Period!!
Period III
Period IV
3.25 O,41
2.78 0.26
3.14 O.29
2.88 O.26
6.47 21.7 5.0k
23.5 3.6
24.4 6.3k
23.8 4,95
5.0 2.25 O.2l
2.01 0,l7
2.07 0.20
2.21 O.l9
3.63 528 62
450 51
448 67
387 70
1260 38.9 6.8
32.4 4.7
33.5 7.2
30.9 5.1
264
3 Period I
Period II
Period III
Period IV
2.64 0.2l
2.40 0.23
2.68 0.47
2.80 0.26
6.12 21.5 3,45
18.2 4.7
21.0 3,95
17.3 4.3
4.7 1.80 0.l7
1.68 0.13
1.79 0.21
1.76 0.14
3.47 371 80
352 48
347 64
389 73
1230 30.4 6.1
24.8 4.3
26.6 4.9
25.0 3.8
258
4 Period!
Period II
Period III
Period IV
2.70 0.59
2.53 0.37
2.07 0.17
2.12 0.10
6.41 9.4 2.4
15.7 2.2
10.8 2.0
12.2 0.9
4.8 1.67 0.14
1.57 0.18
1.44 0.17
1.36 0.12
3,42 364 82
348 67
308 86
336 61
1250 30.3 3.7
25.1 4.6
26.0 5.2
25.7 4.6
239
Controlb 2.11 0.19 6.73 12.4 1.4 4.6 1.39 0.16 3.82 324 72" 1380 23.2 4.3 256
a Each period represents the results of 6 hr of dialysis time; values are means SEM, N =
b Values represent the mean of four dialysates per patient.
N = 10.
d N = 9.
P < 0.001 in comparison to control.
1P <0.005.
S <0.05.
12; D, dialysate; S, serum.
0
0
1.0
1O-1
102
io MGio"
Aib lgG
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Table 4. Relationship between loss of proteins and the peritoneal generation of 6-keto-PGF1,, in dialysate effluent during peritonitis (first day of
treatment) and in the absence of inflammation (controi)a
Total protei&' Albuminb l32Microg1obulinb IgGc a2-Macroglobulin"
Peritonitis
Period I r 0.8841
P <0.001
0.7963
<0.01
0.6742
<0.05
0.7162
<0.01
0.6236
<0.05
Period II r 0.7446
P <0.01
0.7854
<0.01
0.5298
<0.10
0.5970
<0.05
0.6517
<0.05
Period III r 0.5697
P <0.10
0.6340
<0.05
0.3885
>0.10
0.5631
<0.10
0.4279
>0.10
Period IV r 0.2270
P >0.10
0.3671
>0.10
0.2913
>0.10
0.4187
>0.10
0.4013
>0.10
Control r 0.3610
P >0.10
0.3946
>0.10
0.2673
>0.10
04126d
>0.10
0,2875
>0.10
a Eachperiod represents the results of 6 hr of dialysis time; control period represents the results of four dialysates per patient with a dwell time
of 6 hr each.
Correlation coefficients (r) given are calculated by linear regression analysis, b N = 12, c N = 10, d N = 9.
—4
Fig. 2. Relation between dialysate 6-keto-PGF1a and peritoneal loss of
total protein during peritonitis (P < 0.01); closed circles, first 6-hr
period; open circles, second 6-hr period. Each data point represents the
dialysate values in one individual.
The current study confirms our recent observation of the
peritoneal generation of the prostanoids 6-keto-PGF1a, PGE2,
PGF2a, and TXB2 in patients undergoing CAPD [10]. The
increase of prostaglandin and thromboxane release during pen-
tonitis could be diminished by local administration of the
cyclo-oxigenase inhibitor indomethacin together with the dial-
ysis solution. The origin of the arachidonic acid metabolites is
thought to be the peritoneal mesotheium. Recent in vitro
studies by Herman et al [261 and Nolan et al [27] have
demonstrated the capacity of serous tissue, that is, peritoneum,
pericardium, and pleura to generate prostaglandins. The quan-
titative succession of prostanoids in these investigations in
different species corresponded to that observed in the present
1 2 3 4
Total protein, g/6 hr
Fig. 3. Relation between dialysate 6-keto-PGF1a and peritoneal loss of
total protein in the absence ofperitoneal inflammation (P>0,10). Each
data point represents the mean values of four consecutive dialysates in
one individual.
study. Since the predominant prostaglandins found during
peritonitis, prostacyclin, determined as its metabolite 6-keto-
PGF1a, and PGE2 are known to possess vasodilative and
permeability increasing properties [12, 28], it is reasonable that
changes of the peritoneal permeability during peritonitis are
affected by these arachidonic acid metabolites. This hypothesis
is supported by significant positive correlations between dialy-
sate prostanoids and protein losses during the initial phase of
inflammation (Figs. 2 and 3, Table 4). A further indication for
the relationship between prostanoids and peritoneal protein
permeability is the simultaneous reduction of prostanoid gener-
ation and protein loss into the dialysate during local adminis-
tration of the cyclo-oxigenase inhibitor indomethacin. Maher,
Hirszel, and Lasrich [29, 30] recently described an increase of
pentoneal clearances of urea and creatinine in unanaesthetized
y —2.612 + 1.374x
r 0.8841
S
16
12
8
4
0
0
U-
a-
0
a,
S
I
1.6
1.2
I
0.8
Q0
0
a)
CD
0.4
0
.
.
y = 0.672 + 0.096x
r 0.3610
S
S
2 4 6
Total protein, g/6 hr
8 10
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Table 5. Effect of indomethacin on peritoneal protein loss and
dialysate prostanoids during peritonitis and in the absence of
inflammation (control)a
Indomethacin
12.5 mg/liter
dialysis fluid
Total protein
loss
g/24 hr
6-keto-PGF1, PGE2
g/24 hr
Peritonitis —
+
13.80 2.00
9.08 1.041
8.64 1.36
5.28 1.12"
2.12 0.48
1.04 021b
Control —
+
9.44 1.24
8.76 1.52
3.76 0.73
3.24 0.56
0.79 0.16
0.44 0.08"
a Values are means SEM, N = 4 in each group.
b P < 0.05.
normal rabbits after intraperitoneal administration of pharma-
cological doses of POE2. Similar results were obtained after
intraperitoneal instillation of various drugs that result in vaso-
dilation [31—34]. Local administrations of vasoconstrictory act-
ing PGF2a was found to decrease such clearances [30]. These
investigations on the permeability of molecules with molecular
weights below 400 daltons cannot be applied directly to proteins
above 11,000 daltons, but they indicate that prostanoids can
influence peritoneal transport properties by affecting mesen-
tenc blood flow and vascular permeability. In contrast to this,
intraperitoneal as well as intravenous administration of
prostacyclin did not affect peritoneal solute transport [30]. This
could be due to the widespread systemic vasodilation that
overlies the local increase of mesenteric blood flow.
Administration of mefenamic acid, an inhibitor of cyclo-
oxigenase to normal rabbits was without effect on peritoneal
solute clearances [35], possibly due to the simultaneous inhibi-
tion of synthesis of both vasodilative and vasoconstrictive
prostanoids. During peritonitis, the balance between
vasoconstrictor and vasodilator prostanoids is disturbed, as
indicated by the overproportional increase of dialysate PGE2
and 6-keto-PGF1a compared to PGF2,. and TXB2. Inhibition of
synthesis of the predominant vasodilator prostaglandins in the
state of peritonitis may result therefore in a decrease of regional
blood flow, with the consequence of decreased peritoneal
permeability and clearance rates. Corresponding results were
obtained in animal models of tissue trauma. Inhibition of
prostaglandin synthesis by indomethacin was effective in inhib-
iting the capillary leakage of macromolecules and the develop-
ment of edema [36].
Besides arachidonic acid metabolites, biogenic amines and
activated complement factors such as C3a and C5a are believed
to influence vascular permeability and blood flow [9, 37, 38].
Williams and Jose [39] and Ramport et al [40] recently described
interactions between the prostaglandin system and activated
complement factors. C5a was found to induce plasma exudation
independent of the permeability increasing agents histidine and
bradykinin when administered additionally to the vasodilator
prostaglandins POE2 or PG!2 [39]. On the other hand, comple-
ment-derived products are thought to enhance the release of
membrane-bound arachidonic acid, the substrate of cyclo-
oxigenase, and in this way promote the supply of prostaglandins
during inflammation [40].
In summary, the results of our study demonstrate a link
between peritoneal generation of prostanoids and protein loss
into the dialysate in the early phase of CAPD-associated
peritonitis. The increased nonselective peritoneal protein per-
meability observed during inflammation correlates positively
with the augmented local generation of prostaglandins, predom-
inantly prostacycin and PGE2. Inhibition of cyclo-oxigenase
reduces both peritoneal prostanoid generation and protein
losses. On the basis of the present results, it cannot yet be
decided if changes of the peritoneal permeability during inflam-
mation are affected directly by prostanoids or are prostanoid-
mediated, probably via activated complement factors.
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